

# Isoprenaline infusion as a method of induction of atrial fibrillation

<b>Submission date</b> 08/01/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 12/01/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 16/02/2024	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Plain English summary under review

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Study Contact

**Contact details**  
Royal Bournemouth Hospital  
Castle Lane East  
Bournemouth  
United Kingdom  
BH7 7DW  
+44 (0)300 019 8500  
researchsponsorship@uhd.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**  
2014-002290-11

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
18091

# Study information

## Scientific Title

Isoprenaline infusion as a method of induction of Atrial Fibrillation: a randomised controlled trial investigating the use of Isoprenaline to induce an episode of atrial fibrillation

## Acronym

IsoAF study

## Study objectives

This study will investigate a use for a well-established drug called isoprenaline. Some doctors use an intravenous infusion of isoprenaline to cause patients to go into an abnormal heart rhythm called atrial fibrillation. This use is part of a procedure to treat that abnormal rhythm. Although it is reasonable to suppose that isoprenaline will have this effect, its ability to induce atrial fibrillation has never been definitively proven. Using a double blinded, placebo controlled design our study will demonstrate the efficacy of induction of atrial fibrillation using an isoprenaline infusion. In addition, the data collected from this trial will demonstrate whether this effect is consistent in the same subject on different occasions and will characterise the ability of isoprenaline to induce atrial fibrillation in different patient groups.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

14/SC/1171

## Study design

Randomised; Interventional

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Topic: Cardiovascular disease; Subtopic: Cardiovascular (all Subtopics); Disease: Arrhythmia

## Interventions

Isoprenaline

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Isoprenaline

**Primary outcome measure**

Presence or absence of atrial fibrillation

**Secondary outcome measures**

N/A

**Overall study start date**

05/01/2015

**Completion date**

31/12/2015

## **Eligibility**

**Key inclusion criteria**

All participants in all groups:

1. The participant must be willing to comply with the protocol requirements including travelling to the investigating hospital for the attendances required for the study
2. Provision of informed consent
3. Participants must be over 18 years of age

**Group 1 – Paroxysmal Atrial Fibrillation Group**

1. Participants must have a history of arrhythmia with 12 lead ECG or ambulatory ECG monitoring recordings documenting a diagnosis of atrial fibrillation
2. Participants must have a pattern of symptoms and investigation results consistent with a diagnosis of paroxysmal atrial fibrillation

**Group 2 – SVT Ablation Group**

1. Participants must have a history of arrhythmia with documented regular, narrow complex tachycardia available on either 12 lead ECG or ambulatory ECG monitor recording
2. Participants must be listed to undergo an Electrophysiology study with a view to performing an ablation procedure
3. Participants must go on to have an ablation procedure for either AtrioVentricular Reentrant Tachycardia (AVRT) or AtrioVentricular Nodal Reentrant Tachycardia (AVNRT) with a defined procedural endpoint

**Group 3 – Atrial Flutter Ablation Group**

1. Participants must have a history of arrhythmia with 12 lead ECG documentation fulfilling prespecified criteria for diagnosis of common type (cavotricuspid isthmus dependent) atrial flutter

2. Participants must be listed to undergo a cavotricuspid isthmus ablation for common type atrial flutter
3. Participants must go on to have only a cavotricuspid isthmus ablation for common type atrial flutter
4. Sustained bidirectional cavotricuspid isthmus block must have been demonstrated as the endpoint for the ablation procedure

#### Group 4 – Pulmonary Vein Isolation Group

1. Participants must have a history of arrhythmia with 12 lead ECG or ambulatory ECG monitoring recordings documenting a diagnosis of atrial fibrillation
2. Participants must be listed to undergo an ablation procedure for atrial fibrillation with the intent of the attending physician to perform pulmonary vein isolation alone as an ablation strategy
3. Participants must be in sinus rhythm at the time that they enter the Cardiac Electrophysiology Laboratory for their ablation procedure.
4. Participants must have an ablation procedure for atrial fibrillation and this must have involved only ablation to achieve pulmonary vein isolation
5. Pulmonary vein isolation must have been demonstrated as the endpoint for the ablation procedure

#### **Participant type(s)**

Patient

#### **Age group**

Adult

#### **Lower age limit**

18 Years

#### **Sex**

Both

#### **Target number of participants**

Planned Sample Size: 235; UK Sample Size: 235

#### **Key exclusion criteria**

All participants in all groups:

1. Allergy to Isoprenaline
2. Any treatment with Amiodarone in the 3 months prior to ablation procedure
3. Hypertrophic cardiomyopathy
4. Suspected acute myocarditis
5. Uncorrected, severe valvulopathy graded by transthoracic echocardiographic parameters
6. An Acute Coronary Syndrome within the last 6 months
7. Recent (within the last 6 months) or scheduled coronary revascularisation
8. Ongoing angina symptoms without investigations demonstrating the absence of myocardial ischaemia
9. Left ventricular ejection fraction measured at <30%
10. Symptoms of decompensated heart failure syndrome in the last 3 months
11. Severe obstructive lung disease
12. Pregnancy at the time of enrolment or a desire to become pregnant during the study period

13. Reduced life expectancy not associated with cardiovascular disease (less than 1 year)

14. Unable to provide informed consent

#### Group 1 – Paroxysmal Atrial Fibrillation Group

15. Any past history of episode of persistent atrial fibrillation at the time of enrolment to the study

16. Treatment with any antiarrhythmic agent within six half-lives of that agent from before an administration of the study drug infusion

#### Group 2 – SVT Ablation Group

1. Any past history of atrial fibrillation documented on 12 lead ECG or ambulatory ECG monitor

2. Any past history of atrial flutter documented on 12 lead ECG or ambulatory ECG monitor

3. Characterisation of SVT as any arrhythmia other than ANRT or AVNRT

4. Treatment with any antiarrhythmic agent within six half-lives of that agent from the ablation procedure (including intraprocedural use) with the exception of isoprenaline and adenosine

#### Group 3 – Atrial Flutter Ablation Group

1. Characterisation of arrhythmia as any arrhythmia other than cavotricuspid isthmus dependent atrial flutter at the time of ablation

2. Treatment with any antiarrhythmic agent within six half-lives of that agent from the ablation procedure (including intraprocedural use) with the exception of isoprenaline and adenosine

#### Group 4 – Pulmonary Vein Isolation Group

1. Requirement for a more extensive ablation strategy than pulmonary vein isolation alone

2. Intraprocedural treatment with any antiarrhythmic agent with the exception of isoprenaline and adenosine

3. Treatment with any antiarrhythmic agent in the days before the ablation within six half-lives of that agent from the ablation procedure

#### **Date of first enrolment**

05/01/2015

#### **Date of final enrolment**

31/12/2015

## **Locations**

#### **Countries of recruitment**

England

United Kingdom

#### **Study participating centre**

**Royal Bournemouth Hospital**

Castle Lane East

Bournemouth  
United Kingdom  
BH7 7DW

## Sponsor information

### Organisation

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

### Sponsor details

Royal Bournemouth Hospital  
Castle Lane East  
Bournemouth  
England  
United Kingdom  
BH7 7DW

### Sponsor type

Hospital/treatment centre

### ROR

<https://ror.org/03xqffv86>

## Funder(s)

### Funder type

Government

### Funder Name

Bournemouth Cardiac Research Fund

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>	version 4.0	09/09/2014	28/04/2023	No	No
<a href="#">Basic results</a>			16/02/2024	No	No
<a href="#">Other files</a>	Statement from sponsor regarding data quality		16/02/2024	No	No